Roche Holding (RHHBY)
(Delayed Data from OTC)
$30.25 USD
+0.23 (0.77%)
Updated Apr 26, 2024 04:00 PM ET
4-Sell of 5 4
C Value C Growth D Momentum C VGM
Company Summary
Basel, Switzerland-based Roche Holding Ltd. is a leading healthcare company focused on developing and commercializing innovative drugs and diagnostic products and services, which enable the early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments — Pharmaceuticals and Diagnostics.
Pharmaceuticals: Key focus areas in this segment are Oncology, Virology, Inflammation, Metabolism and Neuroscience. The segment accounted for 76% of total sales in 2023.
Diagnostics: The Diagnostics Division operates under five segments — , Core Lab, Molecular Lab, Pathology Lab, Point ...
Company Summary
Basel, Switzerland-based Roche Holding Ltd. is a leading healthcare company focused on developing and commercializing innovative drugs and diagnostic products and services, which enable the early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments — Pharmaceuticals and Diagnostics.
Pharmaceuticals: Key focus areas in this segment are Oncology, Virology, Inflammation, Metabolism and Neuroscience. The segment accounted for 76% of total sales in 2023.
Diagnostics: The Diagnostics Division operates under five segments — , Core Lab, Molecular Lab, Pathology Lab, Point of Care and Diabetes Care. The segment accounted for 24% of total sales in 2023.
In September 2014, Roche acquired InterMune for $8.3 billion and added Esbriet to its portfolio. During the first quarter of 2018, Roche acquired Flatiron Health and Ignyta, Inc. While Flatiron Health enabled accelerated development and delivery of breakthrough medicines for oncology patients, Ignyta’s lead molecule entrectinib (approved under the brand name Rozlytrek) targets tumors with one of two genetically defined gene rearrangements: ROS1 fusions in non-small cell lung cancer (NSCLC) and NTRK fusions across a broad range of solid tumors. In July 2018, the company acquired Foundation Medicine Inc. to broaden its healthcare portfolio and aims to further advance molecular insights and the broad availability of high-quality, comprehensive genomic profiling, both key enablers for the development of new cancer treatments and optimal patient care. Roche’s subsidiary, Genentech, also obtained full rights to Jecure’s entire preclinical portfolio of NLRP3 inhibitors. In December 2019, Roche acquired Spark Therapeutics, Inc. In 2023, Roche acquired Telavant, including rights to the novel TL1A-directed antibody (RVT-3101) from Roivant for the treatment of inflammatory bowel disease.
In December 2023, Roche announced that it would acquire Carmot Therapeutics, which includes three clinical-stage assets with best-in-class potential in obesity (CT-388 and CT-996) and diabetes (CT-868) in its portfolio.
Sales for 2023 came in at CHF 58.7 billion, down 7% from the 2022 level.
General Information
Roche Holding AG
GRENZACHERSTRASSE 124
BASEL, V8 CH-4070
Phone: 41-61-688-1111
Fax: 41-0-61-691-9391
Web: http://www.roche.com
Email: investor.relations@roche.com
Industry | Large Cap Pharmaceuticals |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 3/31/2024 |
Exp Earnings Date | NA |
EPS Information
Current Quarter EPS Consensus Estimate | NA |
Current Year EPS Consensus Estimate | 2.47 |
Estimated Long-Term EPS Growth Rate | 2.50 |
Exp Earnings Date | NA |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 30.02 |
52 Week High | 40.48 |
52 Week Low | 29.80 |
Beta | 0.39 |
20 Day Moving Average | 4,154,432.50 |
Target Price Consensus | 37.75 |
4 Week | -5.23 |
12 Week | -10.90 |
YTD | -16.51 |
4 Week | -2.36 |
12 Week | -13.37 |
YTD | -21.71 |
Shares Outstanding (millions) | NA |
Market Capitalization (millions) | NA |
Short Ratio | NA |
Last Split Date | 2/27/2014 |
Dividend Yield | 2.89% |
Annual Dividend | $0.88 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | 3/14/2024 / $0.88 |
Fundamental Ratios
P/E (F1) | 12.25 |
Trailing 12 Months | NA |
PEG Ratio | 5.00 |
vs. Previous Year | NA |
vs. Previous Quarter | NA |
vs. Previous Year | NA% |
vs. Previous Quarter | NA% |
Price/Book | 6.12 |
Price/Cash Flow | 9.74 |
Price / Sales | NA |
3/31/24 | NA |
12/31/23 | NA |
9/30/23 | NA |
3/31/24 | NA |
12/31/23 | NA |
9/30/23 | NA |
3/31/24 | NA |
12/31/23 | 1.35 |
9/30/23 | NA |
3/31/24 | NA |
12/31/23 | 1.04 |
9/30/23 | NA |
3/31/24 | NA |
12/31/23 | NA |
9/30/23 | NA |
3/31/24 | NA |
12/31/23 | NA |
9/30/23 | NA |
3/31/24 | NA |
12/31/23 | 23.29 |
9/30/23 | NA |
3/31/24 | NA |
12/31/23 | NA |
9/30/23 | NA |
3/31/24 | NA |
12/31/23 | 2.02 |
9/30/23 | NA |
3/31/24 | NA |
12/31/23 | 0.75 |
9/30/23 | NA |
3/31/24 | NA |
12/31/23 | 42.72 |
9/30/23 | NA |